Forskolin for Health & Longevity

Evidence Review created on 04/25/2026 using AI4L / Opus 4.7

Also known as: Coleonol, Colforsin, Coleus forskohlii, Plectranthus barbatus, Makandi, Pashanabhedi

Motivation

Forskolin is a plant-derived compound extracted from the tuberous roots of the Indian coleus plant (Plectranthus barbatus, formerly Coleus forskohlii), a member of the mint family. Its distinguishing feature is that it directly raises a key intracellular signaling molecule, which in turn influences bodily processes most relevant to body composition and eye-pressure regulation.

Coleus forskohlii has been used for centuries in Ayurvedic medicine. The active compound forskolin was first isolated in 1974 at the Central Drug Research Institute in Lucknow, India, and has since traveled two parallel paths: a foundational pharmacological tool in cell biology, and a widely sold dietary supplement promoted for fat loss and heart and metabolic support, with marketing claims that often outrun the underlying clinical trial base.

This review examines the evidence for and against forskolin as an intervention for health and longevity. It spans the molecular mechanisms by which forskolin acts, the small body of human trial data on body composition and intraocular pressure, signals from preclinical and ongoing research, the safety and interaction profile of oral and topical forms, common practical considerations, and the research directions most likely to refine its evidence base.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Forskolin

Grokipedia’s entry provides a structured reference overview of forskolin as a labdane diterpenoid with the molecular formula C22H34O7, covering its 1974 isolation from Coleus forskohlii at the Central Drug Research Institute in India, its activation of adenylate cyclase, and its applications in weight management, glaucoma, and traditional Ayurvedic medicine.

Examine

Coleus forskohlii benefits, dosage, and side effects

Examine.com’s monograph evaluates forskolin (the active diterpene of Coleus forskohlii) primarily for cardiovascular health and body composition, summarizing the small set of human trials, recommending a typical daily dose of 50 mg of forskolin (250 mg of 10% extract twice daily), and flagging cautions around hypotension, antiplatelet effects, and stomach acid.

ConsumerLab

Reviews and Information for Forskolin (Coleus Forskohlii)

ConsumerLab’s forskolin section reports independent testing of commercial Coleus forskohlii products, with documented cases of products containing only a small fraction of their labeled forskolin content, alongside dosing guidance, comparative cost analysis, and warnings on cardiovascular and bleeding interactions.

Systematic Reviews

A small set of systematic reviews has examined forskolin and Coleus forskohlii, focused mainly on glaucoma and metabolic outcomes; the broader supplement evidence base is too thin to support multiple high-quality systematic reviews.

Nutritional Supplementation in the Treatment of Glaucoma: A Systematic Review - Loskutova et al., 2019

Systematic review of 33 intervention trials, including 21 randomized controlled trials (RCTs, trials in which participants are assigned randomly to treatment or control), of nutritional supplements in glaucoma; concludes that forskolin-containing supplements consistently lowered intraocular pressure beyond conventional therapy alone, while emphasizing that overall evidence quality is not yet conclusive.
Insights into Tanning Biology and Tanning Products - Resnick et al., 2026

Systematic review of compounds influencing skin pigmentation that includes forskolin as a topical adenylate-cyclase activator capable of mimicking ultraviolet-light-induced melanogenesis (melanin production), summarizing preclinical mechanism and limited human topical pigmentation studies.

No additional high-quality systematic reviews or meta-analyses focused specifically on forskolin for body composition, cardiovascular endpoints, or longevity outcomes were identified on PubMed as of 2026-04-25. The body-composition literature consists primarily of two small randomized trials and one open-label trial, which is insufficient for a formal meta-analysis.

Mechanism of Action

Forskolin acts through several converging pathways, all anchored in its direct activation of adenylate cyclase:

Direct adenylate cyclase activation: Forskolin binds to and stabilizes most isoforms of adenylate cyclase (an enzyme that converts ATP (adenosine triphosphate, the cell’s main energy carrier) to cyclic adenosine monophosphate). This sharply raises intracellular cAMP (cyclic adenosine monophosphate, a universal intracellular signaling molecule that activates many downstream enzymes), independent of G-protein-coupled receptor activation, which is why forskolin is widely used as a pharmacological tool in cell biology.
Lipolysis via PKA and HSL: Elevated cAMP activates protein kinase A (PKA, an enzyme that adds phosphate groups to other proteins to regulate their activity), which phosphorylates hormone-sensitive lipase (HSL, an enzyme inside fat cells that releases stored fatty acids) and perilipin on the surface of lipid droplets in adipocytes (fat-storage cells). The net effect is increased breakdown of stored triglycerides into free fatty acids and glycerol, the proposed basis for the body-composition effects in human trials.
Cardiac inotropy and vasodilation: In cardiac muscle, increased cAMP enhances calcium influx and contractile force (positive inotropy). In vascular smooth muscle, cAMP-driven activation of myosin light-chain phosphatase causes relaxation, producing modest vasodilation and lower systemic vascular resistance.
Aqueous humor reduction: In the eye, forskolin lowers intraocular pressure (IOP, the fluid pressure inside the eye that, when elevated, damages the optic nerve in glaucoma) by reducing the rate of aqueous humor formation by the ciliary epithelium, an effect demonstrated with both topical and oral administration.
Bronchial smooth muscle relaxation: In airway smooth muscle, increased cAMP relaxes bronchi (the airways of the lungs) and inhibits release of inflammatory mediators from mast cells, providing the mechanistic rationale for the small bronchodilator/asthma trials.
CFTR channel opening: Forskolin-driven cAMP elevation phosphorylates and opens the cystic fibrosis transmembrane conductance regulator (CFTR, a chloride channel mutated in cystic fibrosis). This is the basis of the forskolin-induced swelling assay in patient-derived intestinal organoids used in modern cystic fibrosis research.
Endocrine effects: cAMP elevation in steroidogenic cells acutely increases cortisol and testosterone release in vitro and in some animal models. Whether this translates into a clinically relevant systemic hormonal shift in humans is uncertain, although a small randomized trial in overweight men reported increased serum free testosterone.
Melanogenesis: Forskolin can stimulate melanin (pigment that gives skin its color) synthesis by raising cAMP in melanocytes (skin cells that produce melanin), independently of ultraviolet light, an effect that has been explored as the basis for “sunless tanning” agents and pigmentation modulators.

Pharmacologically, forskolin is a labdane diterpene with molecular formula C22H34O7 and molecular weight ~410 Da. Selectivity: forskolin is non-selective across most adenylate cyclase isoforms (AC1–AC8, with the notable exception of AC9), which is why systemic exposure raises cAMP across many cell types simultaneously rather than in a tissue-specific way. Oral bioavailability: that of pure forskolin is poor and incompletely characterized, which has motivated formulation work (lipid-based, micronized, and the water-soluble derivative colforsin daropate). Half-life: the plasma half-life of intravenously administered forskolin or its derivatives is short, on the order of minutes to a few hours. Metabolism: hepatic biotransformation is the primary clearance pathway, with available in vitro and animal data implicating cytochrome P450 (CYP450, a family of liver enzymes that metabolize most drugs) isoforms — most consistently CYP3A4 (a major liver enzyme that metabolizes many drugs) — alongside Phase II glucuronidation; the precise quantitative contribution of each enzyme in humans has not been definitively mapped. Tissue distribution: as a highly lipophilic diterpene, forskolin distributes broadly across tissues — including adipose, cardiac, vascular, ocular, hepatic, and central nervous system compartments — consistent with its widespread cAMP-elevating activity rather than acting on a single organ; it shows no known selective tissue accumulation in humans.

Historical Context & Evolution

Coleus forskohlii (now Plectranthus barbatus) has been used in Ayurvedic medicine for at least two millennia under names such as Makandi and Pashanabhedi, with traditional indications spanning heart conditions, respiratory complaints, urinary disorders, and skin diseases. The plant’s tuberous root was the part most commonly prepared as a decoction or powder.

In 1974, researchers at the Central Drug Research Institute (CDRI) in Lucknow, India — Tandon and colleagues — isolated a bioactive diterpene from the root that they initially named coleonol. In 1977, a team at Hoechst India Limited led by Sujata V. Bhat re-elucidated the structure and renamed the compound forskolin to honor Peter Forsskål, the 18th-century Swedish naturalist who first described the plant genus. Hoechst (now Sanofi) initially developed forskolin as a candidate cardiovascular drug for congestive heart failure, where its positive inotropic and vasodilatory profile was attractive. Brief clinical investigation in patients with idiopathic congestive cardiomyopathy in the late 1980s found short-term hemodynamic improvements, but oral bioavailability and the development of safer alternatives (ACE inhibitors (angiotensin-converting enzyme inhibitors, a class of blood-pressure-lowering drugs), beta-blockers) led the cardiovascular program to be abandoned. The water-soluble derivative colforsin daropate hydrochloride was eventually approved in Japan as an intravenous inotropic agent for acute heart failure.

Throughout the 1980s and 1990s, forskolin established itself as a foundational laboratory tool in cell biology, used in countless studies to elevate cAMP and probe G-protein-coupled receptor pharmacology. Therapeutic interest then re-emerged in two largely separate streams. In ophthalmology, topical forskolin and oral forskolin–rutin combinations were investigated as adjunctive intraocular-pressure-lowering agents in open-angle glaucoma, including small open-label and double-blind trials and a multicenter Italian study by Vetrugno and colleagues in 2012 that became a key reference for the supplement category. In nutrition, the publication by Godard and colleagues in 2005 — using the patented Sabinsa ForsLean extract, whose manufacturer has a direct financial interest in trial outcomes that favor the branded preparation — showing favorable changes in body fat percentage and free testosterone in overweight men launched a wave of consumer interest, weight-loss-supplement marketing, and high-profile media promotion. The subsequent record has been mixed: a parallel 2005 trial by Henderson and colleagues in mildly overweight women did not show significant fat-mass changes; a 2015 trial by Loftus and colleagues in overweight and obese subjects showed favorable insulin and HDL (high-density lipoprotein, the cardioprotective “good” cholesterol) effects on a hypocaloric diet without significant weight reduction beyond placebo; and consumer-protection and academic reviews have repeatedly emphasized the small overall trial base.

In parallel, forskolin has remained an important in vitro tool in modern cystic fibrosis research, where forskolin-induced swelling of patient-derived intestinal organoids is now used to characterize CFTR function and predict response to CFTR modulators. Forskolin itself was also tested in the National Institute on Aging’s Interventions Testing Program (ITP, a multi-site program that tests compounds for lifespan extension in genetically diverse mice) and did not extend median lifespan in the genetically heterogeneous UM-HET3 mouse cohort, a result that distinguishes its longevity-relevant signal from compounds such as rapamycin or acarbose.

Expected Benefits

High 🟩 🟩 🟩

Intraocular Pressure Reduction

Forskolin lowers intraocular pressure when applied topically or taken orally as part of forskolin–rutin combinations. The Loskutova et al. (2019) systematic review of nutritional supplementation in glaucoma concluded that forskolin-containing supplements consistently reduced intraocular pressure beyond conventional therapy alone. Open-label and randomized clinical trials of 1% forskolin eye drops in open-angle glaucoma showed average reductions of approximately 4.5–5.4 mmHg from baseline, and oral forskolin–rutin in patients on maximum tolerated medical therapy produced an additional 10–15% reduction in patients above target intraocular pressure. The mechanism — reduced ciliary aqueous-humor formation — is well characterized and pharmacologically distinct from beta-blockers and prostaglandin analogues.

Magnitude: Approximately 4.5–5.4 mmHg absolute reduction with topical 1% forskolin; approximately 10–15% additional reduction with oral forskolin–rutin in patients on maximum tolerated topical therapy.

Medium 🟩 🟩

Body Composition Changes in Overweight Men ⚠️ Conflicted

Godard et al. (2005), a 12-week randomized, double-blind, placebo-controlled trial in 30 overweight and obese men using 250 mg of 10% forskolin extract twice daily — specifically the patented Sabinsa ForsLean preparation, whose manufacturer has a direct financial interest in trial outcomes that favor the branded extract — showed significant decreases in body fat percentage and fat mass measured by dual-energy X-ray absorptiometry (DXA, an imaging method used to measure body composition and bone density), a trend toward increased lean mass, and an increase in serum free testosterone in the forskolin group. A parallel trial by Henderson et al. (2005) in 23 mildly overweight women using the same regimen did not reproduce significant fat-mass changes; the Loftus et al. (2015) 12-week mixed-sex trial in overweight and obese adults on a hypocaloric diet showed favorable improvements in insulin and HDL but no weight or fat-mass advantage over placebo. The conflict across sexes and study designs is unresolved, which is the basis for the “Medium / conflicted” classification.

Magnitude: Approximately 4 percentage points greater reduction in body fat percentage and roughly 4 kg fat-mass advantage versus placebo in overweight men in the Godard trial; no significant advantage in the comparable women’s trial.

Insulin Sensitivity Improvements

In the Loftus et al. (2015) randomized controlled trial of 250 mg Coleus forskohlii extract twice daily for 12 weeks alongside a hypocaloric diet in overweight and obese adults, the forskolin arm showed statistically significant improvements in fasting insulin concentration and the homeostatic model assessment of insulin resistance (HOMA-IR, a calculated index of insulin resistance from fasting glucose and insulin) compared with placebo. HDL cholesterol (high-density lipoprotein, the cardioprotective “good” cholesterol) increased similarly in both arms and was not a forskolin-specific effect. The mechanistic rationale — cAMP-mediated increase in lipolysis and modest reductions in adipose-tissue free fatty-acid efflux to the liver — is biologically coherent.

Magnitude: Statistically significant reductions in fasting insulin and HOMA-IR versus placebo over 12 weeks in a mixed-sex overweight cohort.

Low 🟩

Asthma Attack Prevention ⚠️ Conflicted

Two single-blind clinical trials from the same Mexican research group examined oral forskolin (10 mg/day) for asthma prevention. González-Sánchez et al. (2006) in 40 patients with mild-to-moderate persistent asthma reported significantly fewer asthma attacks on forskolin (40%) versus inhaled sodium cromoglycate (85%) over 6 months, with similar lung function. Huerta et al. (2010) in 60 adult patients found that 2 months of oral forskolin did not significantly improve any pulmonary function parameter compared with inhaled beclomethasone, while beclomethasone produced small, statistically significant improvements in forced expiratory volume and forced vital capacity. The two trials reach different conclusions, the comparator drugs differ, and both are single-blind designs from one research group; this is the basis for the “Low / conflicted” classification.

Magnitude: 45 percentage-point lower asthma-attack incidence versus sodium cromoglycate in the González-Sánchez trial; no significant pulmonary-function benefit versus beclomethasone in the Huerta trial.

Acute Hemodynamic Improvement in Heart Failure

Intravenous forskolin (HL 362) and the water-soluble derivative colforsin daropate hydrochloride produce short-term increases in cardiac output and reductions in systemic vascular resistance in patients with idiopathic congestive cardiomyopathy and acute heart failure. The 1980s comparative work versus dobutamine and sodium nitroprusside showed comparable short-term hemodynamic effects without arrhythmia exacerbation. Colforsin daropate is approved as an intravenous inotrope for acute heart failure in Japan; oral forskolin has not been shown to produce equivalent cardiovascular effects in chronic outpatient settings.

Magnitude: Short-term increases in cardiac index of approximately 30–60% with intravenous administration in idiopathic congestive cardiomyopathy; oral magnitude in chronic heart failure is not established.

Speculative 🟨

Topical Skin Pigmentation and “Sunless Tanning”

Topical forskolin can stimulate melanogenesis in animal models and has been included in some experimental sunless-tanning formulations, with the appeal of inducing eumelanin (the dark pigment that protects skin from ultraviolet damage) without ultraviolet exposure. Human topical pigmentation data are limited and largely confined to small mechanistic studies. Whether this translates into a meaningful protective or cosmetic effect in humans is unresolved.

Bone Mass Preservation

The Godard et al. (2005) trial reported a small but statistically significant increase in total bone mass on DXA in overweight men receiving forskolin compared with placebo over 12 weeks. The biological plausibility (cAMP signaling in osteoblasts (bone-forming cells) and effects on receptor-linked osteogenic signaling) is reasonable, but no controlled trials in humans have replicated this finding or extended follow-up to clinically meaningful bone outcomes.

Erectile Function Support in Refractory Vasculogenic Impotence

A small open-label series by Mulhall et al. (1997) explored intracavernosal forskolin as a salvage agent in men with vasculogenic erectile dysfunction not responding to standard three-agent intracavernosal therapy and reported improved erectile responses in some participants. This is a niche, urology-clinic-only application; oral forskolin has not been shown to support erectile function in controlled trials.

Cognitive and Long-Term-Potentiation Support

Forskolin reliably enhances long-term potentiation (LTP, a cellular mechanism of memory formation in the brain) in animal models by elevating cAMP in hippocampal neurons. Human controlled trials of oral or sublingual forskolin for cognition or memory are absent, and any human cognitive benefit at standard supplement doses is speculative.

Benefit-Modifying Factors

Sex: The two parallel 2005 randomized trials suggest a male-biased body-composition response: significant fat-mass and free-testosterone changes in overweight men, but not in mildly overweight women. Whether this represents a true sex effect, baseline-adiposity effect, or trial-design effect is unresolved.
Baseline body fat and metabolic status: Larger absolute body-composition responses appear in individuals with greater baseline adiposity and higher fasting insulin or HOMA-IR. Lean, metabolically healthy adults are unlikely to see meaningful body-composition or insulin effects.
Co-intervention with caloric restriction: Forskolin’s most consistent metabolic effects in human trials occur on a hypocaloric diet (Loftus et al. 2015). As a stand-alone intervention without dietary change, body-composition effects are not reliably demonstrated.
Baseline intraocular pressure: Greater absolute intraocular-pressure reductions are seen in patients with higher baseline pressures (above 21 mmHg) in the Vetrugno et al. (2012) oral forskolin–rutin study; well-controlled patients see smaller incremental gains.
Age-related considerations: Older adults are over-represented in the glaucoma trials, where forskolin’s intraocular-pressure benefit appears retained; the body-composition trials are in younger adults (mean age in the 30s and 40s), and there are no trials specifically in adults aged 75+ to inform older-adult dosing.
Pre-existing health conditions: Patients with metabolic syndrome and elevated insulin resistance show clearer insulin effects; those with primary open-angle glaucoma already on maximum tolerated medical therapy show clearer intraocular-pressure effects. Lean, normotensive, metabolically healthy adults form the population with the smallest measurable benefit.
Genetic polymorphisms: Pharmacogenetic data on forskolin in humans are essentially absent. Variation in cytochrome P450 isoforms (notably CYP3A4) could plausibly affect systemic exposure, but there is no clinically actionable pharmacogenomic test for forskolin.
Formulation and standardization: Bioactivity depends on the actual forskolin content of the Coleus forskohlii extract, which can vary widely between products; standardized 10% forskolin extracts at validated doses produce more consistent responses than non-standardized “Coleus root powder” preparations.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Blood-Pressure Lowering and Orthostatic Hypotension

Forskolin’s vasodilatory action can produce clinically meaningful reductions in systemic blood pressure, with case reports and reference databases documenting symptomatic hypotension (low blood pressure) and lightheadedness, particularly when standing (orthostatic hypotension, a fall in blood pressure on standing). In the Godard et al. (2005) trial, blood pressure trends were observed in the forskolin group but did not reach statistical significance at the studied dose. The risk is greatest in patients already on antihypertensive therapy or with low baseline blood pressure.

Magnitude: Variable; reported orthostatic effects up to 10 mmHg systolic; risk is concentration- and formulation-dependent and amplified by concurrent antihypertensive medication.

Medium 🟥 🟥

Increased Bleeding Risk via Antiplatelet Effect

Forskolin inhibits platelet aggregation through cAMP elevation in platelets. This is mechanistically additive with aspirin, P2Y12 inhibitors (a class of antiplatelet drugs that block the P2Y12 receptor on platelets, including clopidogrel, prasugrel, ticagrelor), warfarin, direct-acting oral anticoagulants (rivaroxaban, apixaban, dabigatran, edoxaban), and other antiplatelet agents. Standard reference databases (Memorial Sloan Kettering, drugs.com, examine.com) advise against combination with these drugs and recommend discontinuation before elective surgery. Spontaneous bleeding on forskolin monotherapy at typical supplement doses appears uncommon, but combination-related bleeding has been described in case reports.